Our business strategy
We develop novel products in areas of high unmet health needs,to deliver treatments and relieve suffering for longer, healthier lives.
Medicinal plants with a history of use
- Reduces development cost and time
- Reduces risk
- Pharmaceuticals and functional foods
- Novel products
Balanced portfolio
- High value products
- Low cost, rapid development products (orphan pharmaceuticals, functional foods)
- Human and veterinary markets
- Early revenues
Virtual operation
- Internal expertise with outsourced development activities
- Reduces costs/maximises efficiency
- Enhances collaboration with KSAs and specialist contractors worldwide
- Enhances innovative partnering
KSA = Key Scientific Advisor
Partner with charitable organisations
- Reduces development cost
- Enhances collaboration with KSAs
- Validates novel treatments for diseases with high unmet medical need and enhances value
- Non-dilutive funds
